Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Thiogenesis Therapeutics Corp. has announced progress in its clinical programs for mitochondrial diseases, highlighting its upcoming Phase 2 trial for MELAS in Europe and a planned Phase 2a trial for Leigh Syndrome in partnership with a leading US children’s hospital. These developments underscore the company’s commitment to addressing rare mitochondrial disorders using its novel thiol compounds.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.